Kolexia
Louvet Christophe Médecine interne
Louvet Christophe
Médecine interne
Institut Mutualiste Montsouris
Paris, France
248 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Adénocarcinome Tumeurs colorectales Métastase tumorale Tumeurs du pancréas Tumeurs du côlon Tumeurs de l'estomac Tumeurs du foie Tumeurs du rectum Récidive tumorale locale

Collaborateurs

Voir plus
Andre Thierry
Andre Thierry
Hôpital Saint-Antoine, Paris, France
Tournigand Christophe
Tournigand Christophe
Hôpital Henri Mondor, Créteil, France
Hammel Pascal
Hammel Pascal
Hôpital Paul Brousse, Villejuif, France
Bachet Jean Baptiste
Bachet Jean Baptiste
Hôpital Pitie Salpetriere, Paris, France

Industries

Voir plus
MSD
5 collaboration(s)
Dernière en 2023
Amgen
3 collaboration(s)
Dernière en 2020
Pierre Fabre
3 collaboration(s)
Dernière en 2020
Grünenthal
2 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study: Marqueurs Pronostiques et prédictifs de réponse Aux Traitements Chez Les Patients Atteints de Cancer Des Voies Biliaires : Cohorte Multicentrique ACABi PRONOBIL
Essai Clinique (GERCOR (Multidisciplinary Group in Oncology))   03 janvier 2024
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   15 novembre 2023
LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
IDEA: A Phase III Randomized Trial Investigating the Duration of Adjuvant Therapy(3 Versus 6 Months) With the Modified FOLFOX 6 or XELOX Regimens for Patients With Stage III Colon Cancer
Essai Clinique (GERCOR (Multidisciplinary Group in Oncology))   27 septembre 2023
NEONIPIGA: Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma: An Open-label GERCOR Phase II Study
Essai Clinique (BMS)   27 septembre 2023
NIPISAFE: Analysis of the Efficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer: A GERCOR Open-label, Randomized, Non-comparative, Two-stage Phase II Trial (NIPISAFE).
Essai Clinique (BMS)   27 septembre 2023
Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer.
European journal of cancer (Oxford, England : 1990)   09 septembre 2023
CHIVA: Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
Néofirinox: Randomized Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer
Essai Clinique (Unicancer)   30 août 2023
The estimand framework had implications in time to patient-reported outcomes deterioration analyses in cancer clinical trials.
Journal of clinical epidemiology   25 août 2023